Experimental drug targets aggressive brain cancer in new trial
Disease control
Recruiting now
This early-stage trial is testing a new drug called RMC-5552 in adults whose aggressive brain cancer (glioblastoma) has returned after standard treatment. The main goals are to find the safest and most effective dose and to see if the drug can help shrink tumors. The study will e…
Phase: PHASE1 • Sponsor: Nicholas Butowski • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC